Erakusten 1 - 10 emaitzak -- 10 bilaketa honetara 'Brendan D Curti', Bilaketaren denbora: 0,07s
Findu emaitzak
-
1
Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab nork William L Redmond, Walter J Urba, John Cha, Yoshinobu Koguchi, Brendan D Curti, Noriko Iwamoto, Takashi Shimada, Shu-Ching Chang, Brian D Piening
Argitaratua 2021-10-01
Artikulua -
2
Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance nork Marcus A. Couey, R. Bryan Bell, Ashish A. Patel, Meghan C. Romba, Marka R. Crittenden, Brendan D. Curti, Walter J. Urba, Rom S. Leidner
Argitaratua 2019-07-01
Artikulua -
3
Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study nork Gregory A Daniels, Sigrun Hallmeyer, Mark Grose, Jon Richards, Mark Faries, Brendan D Curti, Kim A Margolin, Yiwei Zhang, Lynn Feun, Anlong Li, John R Hyngstrom, Robert H I Andtbacka
Argitaratua 2022-12-01
Artikulua -
4
Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells nork Rebekka Duhen, Carmen Ballesteros-Merino, Alexandra K. Frye, Eric Tran, Venkatesh Rajamanickam, Shu-Ching Chang, Yoshinobu Koguchi, Carlo B. Bifulco, Brady Bernard, Rom S. Leidner, Brendan D. Curti, Bernard A. Fox, Walter J. Urba, R. Bryan Bell, Andrew D. Weinberg
Argitaratua 2021-02-01
Artikulua -
5
Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition nork Elizabeth I. Buchbinder, Janice P. Dutcher, Gregory A. Daniels, Brendan D. Curti, Sapna P. Patel, Shernan G. Holtan, Gerald P. Miletello, Mayer N. Fishman, Rene Gonzalez, Joseph I. Clark, John M. Richart, Christopher D. Lao, Scott S. Tykodi, Ann W. Silk, David F. McDermott
Argitaratua 2019-02-01
Artikulua -
6
HDAC inhibition prevents transgene expression downregulation and loss-of-function in T-cell-receptor-transduced T cells nork Tamson V. Moore, Gina M. Scurti, Matthew DeJong, Siao-Yi Wang, Annika V. Dalheim, Courtney R. Wagner, Kelli A. Hutchens, Jodi J. Speiser, Constantine V. Godellas, Chris Fountain, Jessica Fleser, Tarsem Moudgil, Mallory Thomas, David Murray, Brendan D. Curti, Joseph I. Clark, Bernard A. Fox, Michael I. Nishimura
Argitaratua 2021-03-01
Artikulua -
7
Systemic immunostimulation induces glucocorticoid-mediated thymic involution succeeded by rebound hyperplasia which is impaired in aged recipients nork Craig P. Collins, Lam T. Khuat, Gail D. Sckisel, Logan V. Vick, Christine M. Minnar, Cordelia Dunai, Catherine T. Le, Brendan D. Curti, Marka Crittenden, Alexander Merleev, Michael Sheng, Nelson J. Chao, Emanual Maverakis, Spencer R. Rosario, Arta M. Monjazeb, Bruce R. Blazar, Dan L. Longo, Robert J. Canter, William J. Murphy, William J. Murphy
Argitaratua 2024-09-01
Artikulua -
8
A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma nork Sandra Aung, Sigrun Hallmeyer, David F. McDermott, Joseph I. Clark, Howard L. Kaufman, Gregory A. Daniels, Sapna P. Patel, John M. Kirkwood, Ryan J. Sullivan, Marc S. Ernstoff, Brendan D. Curti, Elizabeth I. Buchbinder, Rene Gonzalez, John M. Richart, Anasuya Gunturi, Jessica Perritt, Janice Dutcher, Girald P. Miletello, Joe Lutzky, Michael A. Morse
Argitaratua 2016-11-01
Artikulua -
9
Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in pat... nork Christy Ralph, Sumati Gupta, Matthew Zibelman, Brendan D Curti, Kevin J Harrington, Steven J O'Day, Andrew G Hill, David C Campbell, Gavin M Wright, David E Gerber, Jonathan E Rosenberg, Jaime R Merchan, Charles M Rudin, Hardev S Pandha, Wallace L Akerley, Daphne Day, Timothy D Clay, Ross R Jennens, Yixin Ren, Emmett V Schmidt, Lisa Guttman
Argitaratua 2023-01-01
Artikulua -
10
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas nork Thomas F Gajewski, John A Thompson, Sanjay Goel, Brendan D Curti, Elisabeth I Heath, Olivier Rixe, David C Smith, Celine Jacquemont, Tycel Phillips, Martin Gutierrez, Sahar Ansari, Andrew L Coveler, Svetomir N Markovic, Timothy M Kuzel, Amitkumar N Mehta, David L Bajor, Hun Ju Lee, Ajay K Gopal, Paolo Caimi, Ariel Topletz-Erickson, Peigen Zhou, Michael W Schmitt, Juneko E Grilley-Olson
Argitaratua 2023-06-01
Artikulua